Skip to main content

Table 1 Patient demographics and characteristics

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

  Overall H101 Control P-Value Overall Survival(%) Median survival(mo) Univariate Multivariate
  1-yr 2-yr   P-Value ExpB (Hazard Ratio ,95 % CI) P-Value
Gender     0.305     0.302   
 Male 159 81 78   67 52 13.0    
 Female 16 6 10   60 30 11.2    
Age     0.948     0.100   
 Median 55.0 55.0 54.5        
  < 60 114 59 55   68 49 12.5    
  ≥ 60 61 28 33   68 56 13.0    
Alpha-foetoprotein(ng/ml)     0.316       
  307.2 269.1 307.2        
Alpha-foetoprotein(ng/ml)     0.947     0.06 1.669(1.178–2.366) 0.004
  ≤ 20 53(30.1 %) 27(30.7) 26(29.5)   89 81 17.6    
 20–400 42(23.9 %) 20(22.7) 22(25.0)   60 45 13.9    
  ≥ 400 80(45.5 %) 40(45.5) 40(45.5)   52 32 9.1    
Child Pugh grade     0.820     0.007 2.132(1.138–3.995) 0.018
 A 154(88.0 %) 76(87.3 %) 78(88.6 %)   70 55 13.3    
 B 21(12.0 %) 11(12.6) 10(11.3)   38 25 7.7    
ALB(g/L)     0.228     0.412   
 Median 40.0 39.6 40.2        
  ≥ 35 131 61 70 0.166 62 50 11.7    
  < 35 44 26 18   67 52 13.3    
Tbil(U/L)     0.386     0.003   
 Median 16.4 16.1 16.8        
  < 20 119 61 58 0.628 75 56 13.7    
  ≥ 20 56 26 30   48 40 8.0    
Virus infection     0.970     0.101   
 none 15 7 8   88 66 13.6    
 HBV 158 79 79   63 51 12.6    
 HCV 2 1 1   50 0 13.9    
Platelet count (10E9/L)     0.630     0.676   
 Median 167.0 179.2 154.5        
  < 100 31 11 20 0.112 63 46 12.2   0.330(0.141–0.773) 0.011
  ≥ 100 144 76 68   67 53 12.8    
No. of tumours     1.000     <0.001 2.024(1.127–3.633) 0.018
  ≤ 3 127 69 70   74 57 13.7    
  > 3 36 18 18   38 30 7.6    
Tumour size (cm)     0.730     0.028 2.936(1.297–6.650) 0.010
  ≤ 5 45 21 24   91 75 18.1    
  > 5 130 66 64   56 42 9.8    
Anti-HBV therapy     0.197     0.424   
 Yes 56 32 24   60 54 13.3    
 No 119 55 64   69 51 9.65    
H101     0.046     0.042 0.593(0.353–0.995) 0.048
 Yes 87 87 0   69 60 12.8    
 No 88 0 88   60 44 11.6    
 BCLC stage     0.453     0.001 2.168(1.322–3.557) 0.002
 A3 1 0 1        
 A4 17 10 7   94 94 17.0    
 B 108 50 58   72 56 12.96    
 C 49 27 22   52 23 6.96    
  1. AFP alpha fetoprotein, ALB serum albumin, HBV hepatitis B virus, HCV hepatitis C virus, TBIL total bilirubin, PVT portal vein thrombosis